Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod for Type 2 Diabetes Mellitus
NCT05307731Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Mar 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fingolimod in type 2 diabetes mellitus (T2DM), sponsored by General Hospital of the Northern Theater Command. Started Mar 2022; status: recruiting.
02
Drugs
fingolimod
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05307731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307731.